David R Webb
Overview
Explore the profile of David R Webb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1816
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ana-Sosa-Batiz F, Verma S, Shafee N, Miller R, Conner C, Hastie K, et al.
EBioMedicine
. 2025 Feb;
113:105619.
PMID: 40020261
Background: Despite the importance of vaccination- and infection-elicited antibodies (Abs) to SARS-CoV-2 immunity, current mouse models do not fully capture the dynamics of Ab-mediated immunity in vivo, including potential contributions...
2.
Verma S, Ana-Sosa-Batiz F, Timis J, Shafee N, Maule E, Pinto P, et al.
EBioMedicine
. 2024 Oct;
108:105361.
PMID: 39353281
Background: Mouse models that recapitulate key features of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection are important tools for understanding complex interactions between host genetics, immune responses, and SARS-CoV-2 pathogenesis....
3.
Willis S, Malaikah S, Bawden S, Sherry A, Sargeant J, Coull N, et al.
Diabetes Obes Metab
. 2024 Jul;
26(9):4030-4042.
PMID: 38978184
Aims: To examine the impact of impaired glycaemic regulation (IGR) and exercise training on hepatic lipid composition in men with metabolic dysfunction-associated steatotic liver disease (MASLD). Materials And Methods: In...
4.
Papamargaritis D, Al-Najim W, Lim J, Crane J, Bodicoat D, Barber S, et al.
Lancet Reg Health Eur
. 2024 May;
39:100853.
PMID: 38803628
Background: An effective prescribing pathway for liraglutide 3 mg, an approved obesity pharmacotherapy, may improve treatment access. This trial compared a targeted prescribing pathway for liraglutide 3 mg with multiple...
5.
Shabnam S, Abner S, Gillies C, Davies M, Dex T, Khunti K, et al.
Diabetes Obes Metab
. 2023 Oct;
26(2):512-523.
PMID: 37857573
Aim: Despite global recommendations for type 2 diabetes mellitus treatment to maintain optimal glycaemic targets, a significant proportion of people remain in suboptimal glycaemic control. Our objective was to investigate...
6.
Shabnam S, Gillies C, Davies M, Dex T, Melson E, Khunti K, et al.
Diabetes Res Clin Pract
. 2023 Aug;
203:110888.
PMID: 37604284
Aim: In this study we aim to identify the factors associated with treatment inertia in patients with type 2 diabetes mellitus (T2DM) who have been recently started on basal insulin...
7.
Davies M, Ahmad E, Lim S, Lamptey R, Webb D
Lancet
. 2023 Jun;
401(10391):1849-1850.
PMID: 37270234
No abstract available.
8.
Ahmad E, Arsenyadis F, Almaqhawi A, Barker M, Jobanputra R, Sargeant J, et al.
Diabet Med
. 2023 Mar;
40(6):e15083.
PMID: 36905324
Aims: We investigated evidence from randomised, placebo-controlled trials of novel glucose-lowering therapies; sodium-glucose co-transporter-2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP4i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), on physical function in...
9.
Conner C, van Fossan D, Read K, Cowley D, Alvarez O, Xu S, et al.
Biochem Pharmacol
. 2023 Mar;
210:115470.
PMID: 36870576
Monoclonal antibodies (mAbs) are one of the fastest-growing classes of drugs and have been approved to treat several diseases, including cancers and autoimmune disorders. Preclinical pharmacokinetics studies are performed to...
10.
Jobanputra R, Sargeant J, Almaqhawi A, Ahmad E, Arsenyadis F, Webb D, et al.
Obes Rev
. 2023 Feb;
24(4):e13553.
PMID: 36721366
Weight-lowering pharmacotherapies provide an option for weight management; however, their effects on physical activity, function, and cardiorespiratory fitness are not fully understood. We conducted a systematic review and meta-analysis of...